Tesamorelin ���景与作用机制 — Common Mistakes

By Editorial Desk · published 2026-06-12 · last reviewed 2026-07-19 · Guide

Everything below concerns 内脏脂肪. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

Background and Pharmacology of Tesamorelin

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.

Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.

Tesamorelin at a glance

Tesamorelin Background and Mechanism

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Related pages on this site

• Adaptive digest
• Regional reference
• Reliable briefing
• Quality handbook
• Adaptive briefing
• Simple review
• Tracked reference
• Tracked casebook

Background and Receptor Mechanism

Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.

Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin Identity And Structure

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

Background from the literature

In May 2012, Starbucks opened its first coffeehouse in Finland, with the location being Helsinki-Vantaa Airport in Vantaa. In August 2013, the first Starbucks inside Dansk Supermarked opened in the department stores Salling in Aalborg and Aarhus in Denmark. In November 2014, Starbucks announced its first Channel Island store, in the primary business area of St Peter Port in Guernsey. On April 21, 2015, Kesko, the second largest retailer in Finland, announced its partnership with Starbucks, with stores opened next to K-Citymarket hypermarkets. As of June 2017, three stores had been opened next to K-Citymarkets: In Sello in Espoo and in Myyrmanni and Jumbo in Vantaa. In February 2016, Howard Schultz announced the opening of stores in Italy. The first Italian Starbucks store was inaugurated in Milan on September 6, 2018, at which point Starbucks already had locations in 78 countries. In May 2016, the first Starbucks store in Slovakia opened in Aupark, in Bratislava. In June 2018, Starbucks announced the opening of stores in Serbia. The first store was opened in April 2019 at Rajiceva Mall. On June 1, 2019, Starbucks opened its first coffee store in Valletta, Malta, the 80th country to have a Starbucks outlet. In July 2025, Starbucks opened its first store in Iceland.

== Publications == Tongraar, A.; Liedl, K. R.; Rode, Bernd M. (1997);"Solvation of Ca2+ In Water Studied By Born-Oppenheimer Ab-Initio QM/MM Dynamics"; J. Phys. Chem. A 1997, 101(35), p. 6299-6309,DOI: 10.1021/jp970963t. Rode, Bernd M.; Schwenk, Christian F., Tongraar, Anan (2004); "Structure and Dynamics of Hydrated Ions - New Insights through Quantum Cechanical Simulation"; J. Mol. Liq. 2004, 110(1-3), pp. 105–122. DOI: 10.1016/j.molliq.2003.09.016. Hofer, Thomas; Pribil, Andreas; Randolf, Bernhard; Rode, Bernd M. (2005); "Structure and dynamics of solvated Sn(II) in aqueous solution - an ab initio QM/MM MD approach", J. Am. Chem. Soc. 2005, 127(41), p. 14231-14238. DOI:10.1021/ja052700f. Rode, Bernd M.; Schwenk, Christian; Hofer, Thomas; Randolf, Bernhard (2005); "Coordination and ligand exchange dynamics of solvated metal ions"; Coord. Chem. Rev. 2005, 249(24), pp. 2993-–3006. DOI: doi:10.1016/j.ccr.2005.03.032. Rode, Bernd M.; Hofer, Thomas (2006); "How to Access Structure and Dynamics of Solutions: The Capabilities of Computational Methods", Pure Appl. Chem. 2006, 78(3), pp. 525–539. DOI: 10.1351/pac200678030525. Rode, Bernd M.; Hofer, Thomas; Randolf, Bernhard; Schwenk, Christian; Xenides, Demetrios; Vchirawongkwin, Viwat(2006); "Ab initio Quantum Mechanical Charge Field (QMCF) Molecular Dynamics - A QM/MM - MD Procedure for Accurate Simulations of Ions and Complexes"; Theor. Chem. Acc. 2006, 115(2-3), pp. 77–85. DOI: 10.1007/s00214-005-0049-1. Hofer, Thomas S.; Randolf, Bernhard R.; Rode, Bernd M.

=== Barrel-aged coffee === In March 2017, Starbucks announced the launch of two new limited-edition specialty drinks made from beans aged in whiskey barrels at its Seattle roastery. Starbucks's barrel-aged coffee were sold with a small batch of unroasted Starbucks Reserve Sulawesi beans, which were then hand-scooped into whiskey barrels from Washington state.

As seen in Fig. 1, the engineered aldehyde tag consists of six amino acids. A set of organisms from all domains of life was chosen and the sequence homology of the sulfatase motif was determined. The sequence used is the best consensus for sequences found in bacteria, archaea, worms and higher vertebrates.

Stores that independently operate locations include Ahold Delhaize, Barnes & Noble, Target Corporation, Albertsons and, more recently, Publix stores. In the EMEA (Europe, Middle East, and Africa) markets, Starbucks operates a franchising program. Different from the licensing program in which existing corporations may apply to operate a Starbucks kiosk within an existing store, franchises can enable new, freestanding stores.

Sources: en.wikipedia.org

Further detail

== External links == Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck: CV Prof. Bernd Michael Rode Curriculum Vita - Prof. Bernd Michael Rode, on the Website of the Theoretical Chemistry Genealogy Project, University of Hannvoer Homepage - Austrian South East Asian University Partnership Networks (ASEA-UNINET) Theoretical Chemistry Genealogy Project Archived 2014-05-20 at the Wayback Machine MOLVISION - Visualization of Chemical Systems APA - Austrian Press Agency: "Hochleistungscomputer für indonesische Partneruniversität"[link removed], published on April, 2nd 2014. Retrieved on May, 23rd 2014 Website of Dr. Heinz Fischer, President of Austria: "Wissenschaftstag" in Ho-Chi-Minh-Stadt, dem früheren Saigon" published by Austrian Press Agency (APA), on May, 31st 2012, retrieved on June, 19th 2014.

On April 11, 2018, Starbucks began operations in Uruguay, with a location in the Montevideo Shopping mall. The company announced that it planned to open up approximately 12 cafes in the country. In August 2019, a franchised location opened in the Cayman Islands. In October 2019, a franchised location opened in the Turks and Caicos Islands. On April 25, 2023, Starbucks commenced operations in Guyana. On April 29, 2024, Starbucks announced its official entry to Ecuador and Honduras in mid-year and late 2024, respectively. On August 14, 2024, Starbucks commenced operations in Ecuador, with its first location in the country at Scala Shopping Mall in Quito. The company announced the plans of opening four more cafes in the capital city until the end of 2025. In July 2026, Starbucks opened its first location in Guayaquil, and now has 10 stores across the country.

== External links == Gastrin-Releasing+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Nosek TM. "Section 6/6ch2/s6ch2_35". Essentials of Human Physiology. Archived from the original on 2016-03-24.

The side effects of ketoconazole are sometimes harnessed in the treatment of non-fungal conditions. While ketoconazole blocks the synthesis of the sterol ergosterol in fungi, in humans, at high dosages (>800 mg/day), it potently inhibits the activity of several enzymes necessary for the conversion of cholesterol to steroid hormones such as testosterone and cortisol. Specifically, ketoconazole has been shown to inhibit cholesterol side-chain cleavage enzyme, which converts cholesterol to pregnenolone, 17α-hydroxylase and 17,20-lyase, which convert pregnenolone into androgens, and 11β-hydroxylase, which converts 11-deoxycortisol to cortisol. All of these enzymes are mitochondrial cytochrome p450 enzymes. Based on these antiandrogen and antiglucocorticoid effects, ketoconazole has been used with some success as a second-line treatment for certain forms of advanced prostate cancer and for the suppression of glucocorticoid synthesis in the treatment of Cushing's syndrome. However, in the treatment of prostate cancer, concomitant glucocorticoid administration is needed to prevent adrenal insufficiency. Ketoconazole has additionally been used, in lower dosages, to treat hirsutism and, in combination with a GnRH analogue, male-limited precocious puberty. In any case, the risk of hepatotoxicity with ketoconazole limits its use in all of these indications, especially in those that are benign such as hirsutism. Ketoconazole has been used to prevent the testosterone flare at the initiation of GnRH agonist therapy in men with prostate cancer.

Sources: en.wikipedia.org

Supporting material

The Cherokee Nation has legislative, executive and judicial branches with executive power vested in the principal chief, legislative power in the Tribal Council, and judicial power in the Tribal Supreme Court. The principal chief, deputy chief, and tribal council are elected to four-year terms by the registered tribal voters over the age of 18. The nation's current system of government was established by the constitution of 1999, which was adopted by tribal citizens in 2003, and implemented in 2006. Every 20 years, the constitution requires a vote among tribal members, to decide whether a new constitutional convention should be held. The Congress of the United States, the federal courts, and state courts have repeatedly upheld the sovereignty of Native Tribes, defining their relationship in political rather than racial terms, and have stated it is a compelling interest of the United States. This principle of self-government and tribal sovereignty is controversial. According to the Boston College sociologist and Cherokee, Eva Marie Garroutte, up to 32 separate definitions of "Indian" are used in federal legislation, as of a 1978 congressional survey. The 1994 Federal Legislation AIRFA (American Indian Religious Freedom Act) defines an Indian as one who belongs to an Indian Tribe, which is a group that "is recognized as eligible for the special programs and services provided by the United States to Indians because of their status as Indians."

Cordelia, afraid that her brother might tell him of James' grandfather, eavesdrops on her brother and Charles' conversation and finds out that Alastair and Charles are gay and Charles was marrying Ariadne for power only. He was scared of rejection by the society and hence couldn't publicly display his sexual orientation. The next morning, James visits Cordelia and they, along with Matthew and Lucie pay a visit to Emmanuel Gast. However, he is already dead. Lucie summons his ghost and learns that he had raised the demon who was wreaking havoc over London. He claimed that he knew her grandfather, but she banished him before he could reveal much. Later they find splinters of wood with strange inscriptions. The four head back to the institute. Charles arrives in a carriage, bringing Grace and a bloodied Tatiana to the Institute. Once Tatiana is being treated in their infirmary, Grace pulls James aside to talk to him. James takes Grace aside where she informs him that she is now engaged to Charles - who had broken off his engagement with Ariadne whilst she was unconscious. Grace demands her bracelet back from him and when he returns it, he feels physical pain from the separation. He goes to the Blackfriars Bridge to relieve his heartache. Grace finds Matthew and tells him what has transpired. Before she leaves, she seemingly holds Matthew in place with words alone and kisses him. She threatens to tell James about this kiss if Matthew ever breathes a word of their conversation to anyone.

== Research == JRT is being investigated as a possible treatment for schizophrenia. According to David E. Olson, his laboratory is also evaluating JRT in additional therapeutic indications, optimizing its synthesis, and developing further analogues of JRT with potentially improved properties.

Sources: en.wikipedia.org

Frequently asked questions